Try one of the below options to narrow down your search.
 |
Documents may be browsed by date, eg; Today, May, 2013.
Past years can be browsed too, eg; 2012, 2011, 2010, 2009 ...
Documents can be searched within a period by browsing to the date and then using the search form; or by direct links, eg; Media releases from 2013
Document tags (shown below the document date, eg; Schedule, SAForms, consultation ...) have highest priority when search results are ranked, followed by title, abstract and full text of document.
Parentheses and the keywords and, or and not have special meaning in search terms. And is implicit and can be omitted; or must be specified.
Remember to group or statements with parentheses if they are beside and statements.
Search examples
- consultation
- Search for consultations
- media and not antibiotics
- Search for media related documents that don't mention antibiotics.
- (media or consultation) and vaccines
- Search for media releases and consultation documents mentioning vaccinations.
Search term:
2004
PHARMAC documents that matched your search:
New treatment for Hepatitis C patients
(1 page, 36 KB)
2004/02/03
A new and more effective combination treatment for people with Hepatitis C is to be funded by Government drug-buying agency PHARMAC. From 1 March pegylated interferon in combination with ribavirin will be available fully funded.
Cancer patients get new funded treatment
(1 page, 36 KB)
2004/02/02
People with an aggressive form of cancer have a new treatment available from today (1 February). An agreement between Government drug- funding agency PHARMAC and pharmaceutical supplier Roche Products (NZ) Ltd will see rituximab (Mabthera) fully funded for all patients with a form of lymphoma (CD20 positive diffuse large B-cell Non-Hodgkins Lymphoma), when it is used in combination with the existing multiple chemotherapy (known as CHOP).
2004-02 PTAC Minutes
(12 pages, 81 KB)
2004/02/01
February 2004: PTAC minutes for web publishing PTAC minutes are published in accordance with the following definitions from the PTAC Guidelines 2002: ““Minute” means that part of the record of a PTAC or Sub-committee meeting (including meetings by teleconference and…
New Hospital Pharmaceutical Assessment Template
(8 pages, 509 KB)
2004/01/12
The New Hospital Pharmaceutical Assessment Process (NHPAP) was developed as part of the Hospital Strategy. The process relies on DHB hospital and pharmaceutical suppliers submitting applications on new hospital pharmaceuticals to PHARMAC for national assessment. This assessment form is designed for DHB hospitals to enable simple and consistent reporting of new hospital pharmaceuticals for national assessment by PHARMAC.
New Hospital Pharmaceutical Assessment Template
(18 pages, 583 KB)
2004/01/12
The New Hospital Pharmaceutical Assessment Process (NHPAP) was developed as part of the Hospital Strategy and requires that pharmaceutical suppliers inform PHARMAC and hospitals of new hospital pharmaceuticals that are available. This assessment form is designed for suppliers to enable simple and consistent reporting of new hospital pharmaceuticals for national assessment by PHARMAC
Latest tender expected to deliver further health savings
(1 page, 36 KB)
2004/01/08
Further savings and ensured supply of medicines are expected to result from the 200304 PHARMAC tender, which has been issued to pharmaceutical suppliers.
AstraZeneca proposal regarding Betaloc CR, Bricanyl, Pilmicort & Oxis 6 mg
(1 page, 43 KB)
2004/01/05
Further to the consultation letter dated 23 December 2003 on the AstraZeneca provisional agreement relating to the supply of Bricanyl 250µg Turbuhaler, Oxis 6µg Turbuhaler, Pulmicort 100µg, 200µg and 400µg Turbuhalers, and Betaloc CR 23.75mg, 47.5mg, 95mg, and 190mg tablets.
NZ public responding to antibiotics message
(1 page, 36 KB)
2004/01/05
People are now less likely to expect an antibiotic to treat colds or flu than they were three years ago, research carried out by Colmar Brunton has found.
Roche proposal regarding rituximab (Mabthera)
(2 pages, 40 KB)
2004/01/05
PHARMAC has signed a provisional amendment to the existing hospital supply agreement with Roche Products (New Zealand) Limited involving the widening of access to rituximab (Mabthera) to include CD20 positive, diffuse large cell B-cell Non-Hodgkin’s Lymphoma (NHL) in combination with CHOP (cyclophosphamide, vincristine, doxorubicin and prednisone) in Part V of Section H of the Pharmaceutical Schedule.
